Astrazeneca's revolutionary cancer drug Trimelimumab is now available in the UAE.

Global pharmaceutical company AstraZeneca has announced the launch of its new breakthrough drug IMJUDO® (tremelimumab) in the United Arab Emirates. This milestone makes the UAE one of the first countries in the Middle East to gain access to this drug. This pharmaceutical innovation represents a breakthrough in cancer treatment as it targets multiple tumors. Clinical trials have shown that IMJUDO® is effective in treating a variety of cancers, including small cell lung cancer and bile duct cancer. The drug has demonstrated demonstrable results in increasing patients' progression-free survival and overall life expectancy, which''provides patients with better therapeutic solutions and improves their quality of life.

AstraZeneca held a series of workshops and sessions to introduce the new drug to healthcare experts in the UAE. More than 100 healthcare professionals working in leading medical institutions involved in cancer treatment participated in these sessions. In these sessions, regional and international healthcare experts presented groundbreaking data from the use of combination immunotherapy to improve survival rates in liver and lung cancer patients who urgently need new and effective drug options, highlighting that this need is still not''satisfied.

The launch of IMJUDO® in the UAE is in line with the growing focus on high quality care for patients with cancer. As directed by the Ministry of Health and Public Protection, the UAE continues to implement comprehensive strategic plans to improve the level of care for cancer patients and develop new innovative diagnostic and treatment methods.

The launch of this innovative drug reflects AstraZeneca's commitment to drive fundamental change in the complete care of cancer patients in the UAE and the Middle'The company focuses on improving therapeutic outcomes for patients and the well-being of their families. IMJUDO® is the fruit of these efforts.

Sameh Fenjeri, AstraZeneca's Regional Director for the Gulf Cooperation Council and Pakistan, said, "At the heart of our message at AstraZeneca is to continue to work with our partners to improve the health and well-being of communities, their residents and the world. Our ongoing collaboration with the Ministry of Health and Public Protection reaffirms our strong commitment to accelerate cutting-edge innovation in the UAE and the region, building on our strategic goal of finding effective treatments for cancer and preventing its lethal outcomes.''We are proud of our presence in the UAE for more than 40 years and the achievements we have made in that time, so that together we can provide the country with the latest medical solutions.'

Dr. Hamid Al Shamsi, Chairman of the UAE United Association of Oncologists, said, "The IMJUDO® drug is an important step in support of global initiatives to fight various forms of cancer, especially since the primary data supporting the efficacy of this breakthrough drug shows its status as the first and only approved drug for use with IMFINZI®, whose data, analyzed over a three-year period, shows its efficacy as a first-line treatment for differentiated or nonresectable'liver cell carcinoma. This is the UAE's leading position in cancer care in the Middle East and globally. We look forward to the positive results that IMJUDO® will bring and continue to work with AstraZeneca to counter the challenges of cancer. "

AstraZeneca is committed to making every effort to ensure the availability of IMJUDO® in the UAE and facilitate its accessibility by continuing to work with healthcare providers, policy makers and patient support organizations to spread awareness of the drug and its role in enhancing care for patients with cancer.